Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 10/20 | 0.40 |
| ▸ | GYS1 | P13807 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010173 | 0.89 | POLB (0.50) | POLBL3MBTL1BCHEGYS1NPC1 | |
| SCHEMBL2011581 | 0.87 | POLB (0.55) | POLBL3MBTL1GYS1MAPT | |
| SCHEMBL12585477 | 0.80 | PPARD (0.47) | POLBL3MBTL1BCHENPC1MAPT | |
| SCHEMBL2011674 | 0.78 | MAPT (0.67) | POLBL3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL2009245 | 0.77 | POLB (0.54) | POLBL3MBTL1GYS1MAPT | |
| SCHEMBL18975048 | 0.77 | MAPT (0.54) | L3MBTL1BCHENPC1MAPTRAB9A | |
| SCHEMBL12585857 | 0.76 | GYS1 (0.67) | POLBL3MBTL1GYS1 | |
| SCHEMBL12585854 | 0.76 | GYS1 (0.67) | POLBL3MBTL1GYS1 | |
| SCHEMBL1756392 | 0.71 | POLB (0.52) | POLBL3MBTL1GYS1NPC1MAPT | |
| SCHEMBL17414635 | 0.70 | POLB (0.51) | POLBL3MBTL1GYS1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | POLB 1431/4885L3MBTL1 4603/4885BCHE 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.